During early-stage drug discovery, novel compounds and intermediates often have limited toxicological data, so how do chemists and safety professionals protect themselves?
Join Senior Scientist Wen Hu of AbbVie as he builds from the ground up, introducing key occupational toxicology principles, exposure banding concepts, and worker safety decision-making frameworks. Using Topoisomerase I inhibitors and their synthetic intermediates as a case study, this webinar will demonstrate how New Approach Methodologies (NAMs) can help with early occupational hazard classification. Register now to understand how NAM-based risk assessment is transforming occupational safety practices in pharmaceutical research.
This ACS Webinar is moderated by Jedd Hillegass of Bristol-Myers Squibb and co-produced by the ACS Green Chemical Institute. As part of ACS's ongoing celebration of our 150th anniversary, this month we reaffirm our commitment to safety by elevating lab protocols, chemical risk awareness, and environmental health standards.
What You Will Learn
- The fundamentals of occupational toxicology and exposure banding, including how Occupational Exposure Bands (OEBs) are assigned and why they matter for safe compound handling in early drug discovery
- How New Approach Methodologies (NAMs) can be used for occupational hazard classification including spanning in vitro assays, Adverse Outcome Pathway mapping, and in silico exposure modeling
- How to apply an integrated NAM-based Early Classification framework to real-world Top1 inhibitor chemotypes and synthetic intermediates with limited toxicological data
Event Details
- Thursday, June 18, 2026 @ 2-3pm ET
- Free to attend
- Slides will be available on day of the webinar
Speaker: Wen Hu
Senior Scientist, AbbVie
Moderator: Jedd Hillegass
Scientific Associate Director, Occupational Toxicology, Bristol-Myers Squibb
Co-Produced With
